Diffuse large B cell lymphoma laboratory tests: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 5: | Line 5: | ||
Laboratory tests of diffuse large B cell lymphoma include:<ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref> | Laboratory tests of diffuse large B cell lymphoma include:<ref name="”seer”">National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov</ref> | ||
* [[Complete blood count]] (CBC) | * [[Complete blood count]] (CBC) | ||
* Blood chemistry studies including LDH and Uric acid | * [[Comprehensive metabolic panel]] | ||
* [[ | * Blood chemistry studies including [[Lactate dehydrogenase|LDH]] and [[Uric acid]] | ||
* [[ | * [[Immunohistochemistry]](IHC) | ||
** CD20, CD3, CD5, CD45, CD10, BCL-2, BCl-6, MYC, IRF-4/ MUM-1, Ki-67 | |||
* [[Flow Cytometry|Flow Cytometry Panel]] (Establishing Reliable Diagnosis require IHC with or without Flow cytometry) | |||
** Kappa/ Lambda, CD3, CD5, CD45, CD10, CD19, CD20 | |||
* IHC for DLBCL subtypes: | |||
** Kappa/ Lambda, CD30, CD138, Cyclin/D1, ALK, HHV-8, SOX-11, EBER-ISH | |||
* [[Cytology]] (for primary CNS lymphoma only) | * [[Cytology]] (for primary CNS lymphoma only) | ||
* [[Genetic testing]] | * [[Genetic testing]] | ||
Line 15: | Line 20: | ||
** Translocations involving ''c-MYC'', ''BCL6'', and ''[[IgH]]'' genes | ** Translocations involving ''c-MYC'', ''BCL6'', and ''[[IgH]]'' genes | ||
* | * Screening tests for HCV and HBV ( to assess risk of Reactivation following immunotherapy/ chemotherapy) are recommended. | ||
* Screening test for HIV | |||
* Screening | |||
==References== | ==References== |
Revision as of 13:41, 17 June 2018
Diffuse large B cell lymphoma Microchapters |
Diagnosis |
---|
Treatment |
Case Studies |
Diffuse large B cell lymphoma laboratory tests On the Web |
American Roentgen Ray Society Images of Diffuse large B cell lymphoma laboratory tests |
Directions to Hospitals Treating Diffuse large B cell lymphoma |
Risk calculators and risk factors for Diffuse large B cell lymphoma laboratory tests |
DLBCL require a complete work-up includes immunophenotypic analysis, cytogenetic analysis (conventional methods and FISH), and molecular diagnostic assays.
Laboratory tests of diffuse large B cell lymphoma include:[1]
- Complete blood count (CBC)
- Comprehensive metabolic panel
- Blood chemistry studies including LDH and Uric acid
- Immunohistochemistry(IHC)
- CD20, CD3, CD5, CD45, CD10, BCL-2, BCl-6, MYC, IRF-4/ MUM-1, Ki-67
- Flow Cytometry Panel (Establishing Reliable Diagnosis require IHC with or without Flow cytometry)
- Kappa/ Lambda, CD3, CD5, CD45, CD10, CD19, CD20
- IHC for DLBCL subtypes:
- Kappa/ Lambda, CD30, CD138, Cyclin/D1, ALK, HHV-8, SOX-11, EBER-ISH
- Cytology (for primary CNS lymphoma only)
- Genetic testing
- Screening tests for HCV and HBV ( to assess risk of Reactivation following immunotherapy/ chemotherapy) are recommended.
- Screening test for HIV
References
- ↑ National Cancer Institute. Surveillance, Epidemiology, and End Results Program 2015. http://seer.cancer.gov